News

FDA clears Papzimeos to treat adult respiratory papillomatosis

The Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent ...

Noodle Recall Update as FDA Issues Risk Warning

The FDA classifies this recall as Class II, which the agency describes as a situation "in which use of or exposure to a ...
Just The News5h

FDA starts 'real-time reporting of adverse event data' for first time

The U.S. Food and Drug Administration has started "real-time reporting of adverse event data," according to an annoucement ...
STAT2d

FDA says it will publish reports of adverse events tied to drugs on daily basis

The FDA said it has begun publishing reports of adverse events concerning drugs on a daily basis, instead of quarterly, as it ...

FDA Announces Recall on Over 20,000 Cans of 7Up—Here’s What to Know

FDA recalls 7Up Zero Sugar Tropical Soda for being mislabeled full-sugar soda. The affected cans were sold in 12-packs in ...

FDA approves use of animal drugs to treat New World Screwworm

The Food and Drug Administration has authorized emergency use of animal drugs to treat and prevent infestations of the New ...

FDA Clears OTC Glucose Monitoring System for Weight Management

System integrates glucose biosensor with an AI-driven platform to show how food, activity, stress, sleep affect the body in ...

A new FDA-approved device could change how Americans lose weight

Kennedy, a skeptic of weight loss drugs, has advocated for dietary and behavioral changes over GLP-1s to reverse the most worrying U.S. health trends. “We think that wearables are a key to the MAHA ...
Fierce Biotech3d

FDA accelerates Stealth Bio's rare disease application with a decision slated for next month

The FDA has accepted Stealth BioTherapeutics’ third new drug application for its ultra rare disease candidate, providing a ...

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Outlook Therapeutics nears FDA decision on Lytenava, with EU sales, exclusivity, and high upside potential despite current ...